Free Trial
NASDAQ:LMAT

LeMaitre Vascular Q3 2025 Earnings Report

LeMaitre Vascular logo
$87.85 +0.98 (+1.13%)
Closing price 10/3/2025 04:00 PM Eastern
Extended Trading
$87.88 +0.03 (+0.03%)
As of 10/3/2025 04:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

LeMaitre Vascular EPS Results

Actual EPS
N/A
Consensus EPS
$0.57
Beat/Miss
N/A
One Year Ago EPS
N/A

LeMaitre Vascular Revenue Results

Actual Revenue
N/A
Expected Revenue
$62.18 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

LeMaitre Vascular Announcement Details

Quarter
Q3 2025
Time
Before Market Opens
Conference Call Date
Thursday, October 30, 2025
Conference Call Time
5:00PM ET

Conference Call Resources

LeMaitre Vascular Earnings Headlines

LeMaitre Vascular: Investment Debate Remains In Place
URGENT: The Market's 3 Red Flags Are Flashing
The warning signs that preceded the 2008 crash are reappearing: an irrational NASDAQ bubble, a record-high gold price (signaling fear), and escalating geopolitical risk. A sharp correction might happen tomorrow, and most investors will be caught off guard. Your portfolio is currently exposed.tc pixel
Why LeMaitre (LMAT) Stock Is Down Today
See More LeMaitre Vascular Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like LeMaitre Vascular? Sign up for Earnings360's daily newsletter to receive timely earnings updates on LeMaitre Vascular and other key companies, straight to your email.

About LeMaitre Vascular

LeMaitre Vascular (NASDAQ:LMAT) is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D. LeMaitre, a vascular surgeon who sought to improve patient outcomes through innovation, the company has introduced numerous technologies that have become standards in surgical practice. Early success with devices such as the LeMaitre valvulotome laid the groundwork for ongoing expansion into complementary product categories. Over the decades, the company has grown both organically and through targeted acquisitions, continuously enhancing its ability to deliver comprehensive solutions for blood flow restoration.

LeMaitre Vascular sells its products worldwide, with direct sales and distribution partnerships spanning North America, Europe, Asia-Pacific and Latin America. Its international footprint allows it to collaborate with hospitals, surgical centers and healthcare systems around the globe, adapting its technology portfolio to meet regional regulatory requirements and clinical preferences. By maintaining a network of field-based clinical specialists and customer support teams, the company ensures that its innovations are effectively integrated into surgical workflows.

Committed to ongoing research and development, LeMaitre Vascular invests in advancing technologies that address unmet clinical needs in vascular surgery. The company’s leadership team brings together expertise in medical device engineering, regulatory affairs and commercial strategy, guiding efforts to expand into new markets and therapeutic areas. Through its focus on quality, innovation and customer partnership, LeMaitre Vascular aims to improve long-term patient outcomes in the treatment of peripheral vascular disease.

View LeMaitre Vascular Profile

More Earnings Resources from MarketBeat